GB9412950D0 - Safety enhancing pharmaceutical compositions - Google Patents

Safety enhancing pharmaceutical compositions

Info

Publication number
GB9412950D0
GB9412950D0 GB9412950A GB9412950A GB9412950D0 GB 9412950 D0 GB9412950 D0 GB 9412950D0 GB 9412950 A GB9412950 A GB 9412950A GB 9412950 A GB9412950 A GB 9412950A GB 9412950 D0 GB9412950 D0 GB 9412950D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
safety enhancing
enhancing pharmaceutical
safety
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9412950A
Other versions
GB2290963A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REDPATH TREVOR H
Original Assignee
REDPATH TREVOR H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REDPATH TREVOR H filed Critical REDPATH TREVOR H
Priority to GB9412950A priority Critical patent/GB2290963A/en
Priority to GB9816045A priority patent/GB2325408B/en
Priority to GB9816046A priority patent/GB2325409B/en
Priority to GB9822734A priority patent/GB2327348A/en
Publication of GB9412950D0 publication Critical patent/GB9412950D0/en
Publication of GB2290963A publication Critical patent/GB2290963A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB9412950A 1994-06-28 1994-06-28 Pharmaceutical uses of ondansetron Withdrawn GB2290963A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB9412950A GB2290963A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of ondansetron
GB9816045A GB2325408B (en) 1994-06-28 1994-06-28 Chewing gum formulation comprising ondansetron
GB9816046A GB2325409B (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron/cyclodextrin complexes
GB9822734A GB2327348A (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9412950A GB2290963A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of ondansetron

Publications (2)

Publication Number Publication Date
GB9412950D0 true GB9412950D0 (en) 1994-10-26
GB2290963A GB2290963A (en) 1996-01-17

Family

ID=10757437

Family Applications (4)

Application Number Title Priority Date Filing Date
GB9816046A Expired - Fee Related GB2325409B (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron/cyclodextrin complexes
GB9412950A Withdrawn GB2290963A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of ondansetron
GB9816045A Expired - Fee Related GB2325408B (en) 1994-06-28 1994-06-28 Chewing gum formulation comprising ondansetron
GB9822734A Withdrawn GB2327348A (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB9816046A Expired - Fee Related GB2325409B (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron/cyclodextrin complexes

Family Applications After (2)

Application Number Title Priority Date Filing Date
GB9816045A Expired - Fee Related GB2325408B (en) 1994-06-28 1994-06-28 Chewing gum formulation comprising ondansetron
GB9822734A Withdrawn GB2327348A (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron

Country Status (1)

Country Link
GB (4) GB2325409B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
DE102010024050B4 (en) 2010-06-16 2014-12-31 Magna Car Top Systems Gmbh Moving roof for a passenger car
CN103919052A (en) * 2014-01-21 2014-07-16 中国人民解放军第三军医大学 Composition used for physical recovery, and its application
US20200054611A1 (en) 2017-01-09 2020-02-20 Gt Biopharma, Inc. Use and composition for treating myasthenia gravis and other myasthenic syndromes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920003064B1 (en) * 1984-01-25 1992-04-13 글락소 그룹 리미티드 Process for preparing hetero cyclic compounds
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy

Also Published As

Publication number Publication date
GB9822734D0 (en) 1998-12-16
GB9816046D0 (en) 1998-09-23
GB9816045D0 (en) 1998-09-23
GB2325409B (en) 1999-02-10
GB2325408B (en) 1999-01-27
GB2325409A (en) 1998-11-25
GB2327348A (en) 1999-01-27
GB2290963A (en) 1996-01-17
GB2325408A (en) 1998-11-25

Similar Documents

Publication Publication Date Title
ZA957247B (en) Pharmaceutical compositions
HU9503199D0 (en) Pharmaceutical basic compositions
HU9500229D0 (en) Pharmaceutical composition against osteoporosis
EP0803255A4 (en) Medicinal composition
IL113329A0 (en) Benzamide-containing pharmaceutical compositions
GB9418609D0 (en) Pharmaceutical compositions
ZA954469B (en) Pharmaceutical compositions
ZA959081B (en) Pharmaceutical compositions
GB9406835D0 (en) Pharmaceutical compositions
GB9412950D0 (en) Safety enhancing pharmaceutical compositions
GB2295825B (en) Pharmaceutical compositions
GB9400047D0 (en) Pharmaceutical compositions
HU9400096D0 (en) Pharmaceutical compositions
GB9822737D0 (en) Safety enhancing pharmaceutical compositions
GB9707483D0 (en) Pharmaceutical compositions
GB2285923B (en) Pharmaceutical compositions containing N-acetal-cysteine
GB9413423D0 (en) Pharmaceutical compositions
GB9401872D0 (en) Pharmaceutical compositions
ZA954838B (en) Pharmaceutical compositions
GB9404457D0 (en) Pharmaceutical compositions
GB9405879D0 (en) Pharmaceutical compositions
GB9406121D0 (en) Pharmaceutical compositions
GB9405948D0 (en) Pharmaceutical compositions
GB9411933D0 (en) Pharmaceutical compositions
GB9407235D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
711Q Appeals lodged - section 117
711R Appeal withdrawn - section 117